DrugPatentWatch Database Preview

Dusa Company Profile

« Back to Dashboard

What is the competitive landscape for DUSA, and what generic alternatives to DUSA drugs are available?

DUSA has one approved drug.

There are four US patents protecting DUSA drugs.

There are twenty-eight patent family members on DUSA drugs in twenty countries.

Summary for Dusa

International Patents:	28
US Patents:	4
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Dusa

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dusa	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes
Dusa	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	6,709,446
Dusa	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	8,216,289
Dusa	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	8,758,418
Dusa	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	7,723,910

Expired US Patents for Dusa

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Dusa	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	8,758,418
Dusa	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	5,079,262
Dusa	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	6,709,446
Dusa	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	5,422,093
Dusa	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	8,216,289

Non-Orange Book US Patents for Dusa

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,223,071	Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
8,030,836	Illuminator for photodynamic therapy
7,190,109	Illuminator for photodynamic therapy
9,723,991	Illuminator for photodynamic therapy

International Patents for Dusa Drugs

Country	Document Number	Estimated Expiration
Czech Republic	298928
Poland	344106
European Patent Office	1510233
Japan	4837826
Turkey	200003233

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Dusa